J Korean Med Sci.  2015 May;30(5):612-616. 10.3346/jkms.2015.30.5.612.

The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children

• Kwon HJ
• Lee SY
• Kim KH
• Kim DS
• Cha SH
• Jo DS
• Kang JH

• KMID: 2155475
• DOI: http://doi.org/10.3346/jkms.2015.30.5.612

Abstract

Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe.

Keyword

Live Attenuated Japanese Encephalitis Vaccine; Immunogenicity; Safety; Children; Clinical Trial

MeSH Terms

Antibodies, Neutralizing/analysis/immunology
Antibodies, Viral/analysis/immunology
Antibody Formation
Child, Preschool
Cohort Studies
Encephalitis, Japanese/*prevention & control
Female
Humans
Infant
Japanese Encephalitis Vaccines/*immunology
Male
Prospective Studies
Vaccination
Vaccines, Attenuated/*immunology
Antibodies, Neutralizing
Antibodies, Viral
Japanese Encephalitis Vaccines
Vaccines, Attenuated

Reference

1. Mackenzie JS, Johansen CA, Ritchie SA, van den Hurk AF, Hall RA. Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr Top Microbiol Immunol. 2002; 267:49–73.

2. Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, van den Hurk AF, Pyke AT, Johansen CA, Mackenzie JS. Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust. 1999; 170:533–536.

3. Schiøler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev. 2007; CD004263.

4. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev Vaccines. 2008; 7:689–693.

5. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med. 1988; 319:608–614.

6. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1993; 42:1–15.

7. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin Biol Ther. 2009; 9:921–931.

8. Lindsey NP, Staples JE, Jones JF, Sejvar JJ, Griggs A, Iskander J, Miller ER, Fischer M. Adverse event reports following Japanese encephalitis vaccination in the United States, 1999-2009. Vaccine. 2010; 29:58–64.

9. Xin YY, Ming ZG, Peng GY, Jian A, Min LH. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg. 1988; 39:214–217.

10. Liu ZL, Hennessy S, Strom BL, Tsai TF, Wan CM, Tang SC, Xiang CF, Bilker WB, Pan XP, Yao YJ, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis. 1997; 176:1366–1369.

11. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol Rec. 2005; 80:242–247.

12. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine. 2000; 18:1–25.

13. Solomon T. Japenese encephalitis vaccine. In : Jong EC, Juckerman JN, editors. Travelers' vaccine. Hamilton, Ont: BC Decker;2004. p. 219–256.

14. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol. 1967; 99:285–290.

15. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine. 2005; 23:5205–5211.

16. Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, Hansen J, Labadie J, Lee L, Martin BL, et al. Brighton Collaboration Fever Working Group, Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine. 2004; 22:551–556.

17. Yaïch M. Investing in vaccines for developing countries: how public-private partnerships can confront neglected diseases. Hum Vaccin. 2009; 5:368–369.

18. Halstead SB, Thomas SJ. Japanese encephalitis: new options for active immunization. Clin Infect Dis. 2010; 50:1155–1164.

19. Tsai TF, Yu YX, Jia LL, Putvatana R, Zhang R, Wang S, Halstead SB. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules. J Infect Dis. 1998; 177:221–223.

20. Sohn YM, Park MS, Rho HO, Chandler LJ, Shope RE, Tsai TF. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine. 1999; 17:2259–2264.

21. Chotpitayasunondh T, Sohn YM, Yoksan S, Min J, Ohrr H. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand. J Med Assoc Thai. 2011; 94:S195–S203.

22. Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, Neuzil KM, Yaïch M, Jacobson J. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine. 2008; 26:2234–2241.

23. Wijesinghe PR, Abeysinghe MR, Yoksan S, Yao Y, Zhou B, Zhang L, Yaich M, Neuzil KM, Victor JC. Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka. Vaccine. 2014; 32:4751–4757.

24. Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet. 2005; 366:1375–1378.

25. Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, Halstead SB. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine. 2007; 25:5041–5045.

26. Japanese encephalitis vaccines. Wkly Epidemiol Rec. 2006; 81:331–340.

27. Jia N, Zhao QM, Guo XF, Cheng JX, Wu C, Zuo SQ, Dai PF, Zhao JY, Zhang JS. Encephalitis temporally associated with live attenuated Japanese encephalitis vaccine: four case reports. BMC Infect Dis. 2011; 11:344.